All Title Author
Keywords Abstract


Efficacy of a Combination of Tanacetum parthenium, 5-Hydroxy Tryptophan and Magnesium (Aurastop) in the Prevention of High Frequency Migraine with Aura

DOI: 10.4236/oalib.1104939, PP. 1-8

Subject Areas: Neurology

Keywords: Migraine Aura, Migraine Therapy, Case-Only Study

Full-Text   Cite this paper   Add to My Lib

Abstract

Object: To verify the efficacy and safety of the new combination of Tanacetum parthenium 150 mg, 5-hydrossitriptophan (5-HTTP) 20 mg and magnesium 185 mg (Aurastop) in the prophylactic treatment of high frequency migraine with aura (MWA). According to the international headache classification (IHCD 3 beta version) the aura phenomena have a duration of 5 - 60 minutes for any of the usual disturbances (visual, somatosensory and speech disturbance) but no classification describes the frequency of this phenomena. Patients who experience migraine aura emphasize the emotional impact of such a phenomenon, mostly because of the severe, though transient, disability caused by the aura symptoms (i.e., inability to work or driving a vehicle). Furthermore, a profound asthenia lasts for about 48 hours after the resolution of the painful phase. Materials and Method: 18 patients (F: n = 10, M: n = 8, mean age: 28) presenting with an ICHD-3 beta diagnosis of migraine with aura (MWA) with a frequency of more than 5 attacks of migraine with aura per month since at least 6 months, were enrolled in the survey and treated with Aurastop© twice a day for a period of 3 months. Diary cards were filled in during a 3-month period before the beginning of the survey and during the 3-month duration of the study. The reduction of MWA attacks per month was assessed as the primary end-point; the reduction of the duration and disability of the aura and of the intensity of the headache were considered as secondary end-points. Results: A statistically significant reduction of MWA attacks/month was observed: more than 95% of the patients referred a reduction >50% of the frequency, 66.6% a reduction of more than 70%, and 16.6% a complete disappearance of the attacks after the first week of therapy. Moreover, a sensible reduction of the duration and disability of the aura phenomena was reported by more than 90% of the patients and, in the 55% of the patients also a reduction of the intensity of the headache. No side effects were reported. The efficacy started to appear during the first month of intake and was maintained during the three months of therapy.

Cite this paper

Volta, G. D. , Zavarise, P. , Perego, L. and Pezzini, A. (2018). Efficacy of a Combination of Tanacetum parthenium, 5-Hydroxy Tryptophan and Magnesium (Aurastop) in the Prevention of High Frequency Migraine with Aura. Open Access Library Journal, 5, e4939. doi: http://dx.doi.org/10.4236/oalib.1104939.

References

[1]  GBD 2015 Neurological Disorder Collaborator Group (2017) Global, Regional and National Burden of Neurological Disorders during 1990-2015; A Systematic Analysis for the Global Burden of Disease Study 2015. Lancet Neurology, 16, 877-897.
[2]  Lipton, R.B., Bigal, M.E., Diamond, M., et al. (2007) Migraine Prevalence, Disease Burden, and the Need for Preventive Therapy. Neurology, 68, 343-349.
https://doi.org/10.1212/01.wnl.0000252808.97649.21
[3]  Website. The International Classification of Headache Disorders. 3rd Edition (Beta Version).
https://www.ichd-3.org/
[4]  D’Andrea, G., Granella, F., Cadaldini, M. and Manzoni, G.C. (1999) Effectiveness of Lamotrigine in the Prophylaxis of Migraine with Aura: An Open Pilot Study. Cephalalgia, 19, 64-66.
https://doi.org/10.1111/j.1468-2982.1999.1901064.x
[5]  Lampl, C., Buzath, A., Klinger, D. and Neumann, K. (1999) Lamotrigine in the Prophylactic Treatment of Migraine Aura—A Pilot Study. Cephalalgia, 19, 58-63 157.
[6]  Pascual, J., Caminero, A.B., Mateos, V., Roig, C., Leira, R., Garci’aMonco, C. and Lai’nez, M.J. (2004) Preventing Disturbing Migraine Aura with Lamotrigine: An Open Study. Headache, 44, 1024-1028.
https://doi.org/10.1111/j.1526-4610.2004.04198.x
[7]  Pittler, M.H. and Ernst, E. (2000) Feverfew for Preventing Migraine. Cochrane Database of Systematic Reviews, No. 1, CD002286.
https://doi.org/10.1002/14651858.CD002286
[8]  Rajapakse, T., et al. (2016) Nutraceuticals in Migraine: A Summary of Existing Guidelines for Use. Headache, 56, 808-816.
https://doi.org/10.1111/head.12789
[9]  Zavarise, P. and Dalla Volta, G. (2017) A Combination of Tanacetum parthenium, Griffonia simplicifolia and Magnesium (Aurastop) as Symptomatic Acute Treat-ment for Migraine Aura: A Retrospective Cohort Study. Open Access Library Journal, 4, e3660.
[10]  Merlo, P., Maggioni, F., Zanchin, G., et al. (2017) Efficacy in Episodic Migraine Prevention of a Combination of Tanacethum p Arthenium, 5-Hydroxy Tryptophan and Magnesium (Aurastop). A Multicentric Observational Study. Journal of Headache and Pain, 18, 202.
[11]  Zavarize, P., Pezzini, A. and Dalla Volta, G. (2017) Combination of Tanacethum p Artenium, 5-Hydrossitriptophan (5-Http) and Magnesium in the Prophylaxis of Episodic Migraine without Aura (AURASTOP) An Observational Study. International Journal of Neurology and Brain Disorders, 4, 1-4.
https://doi.org/10.15436/2377-1348.17.1630
[12]  Dalla Volta, G., et al. (2018) AURASTOP in the Treatment of Migraine Aura. International Journal of Neurology and Brain Disorders, 5, 11-14.
[13]  Csáti, A., Edvinsson, L., Vécsei, L., Toldi, J., Füloi, J. and Warfvinge, K. (2015) Kynurenic Acid Modulates Experimentally Induced Inflammation in the Trigeminal Ganglion. Journal of Headache and Pain, 16, 99.
https://doi.org/10.1186/s10194-015-0581-x
[14]  Chauvel, V., et al. (2012) Effect of Systemic Kynurenine on Cortical Spreading Depression and Its Modulation by Sex Hormones in Rat. Experimental Neurology, 236, 207-214.
https://doi.org/10.1016/j.expneurol.2012.05.002
[15]  Olàh, G., Herédi, J., Menyhàrt, A., Czinege, Z., Nagy, D., Fuzik, J., Kocsis, K., Knapp, L., Krucsò, E., Gellért, L., Kis, Z., Farkas, T., Fulop, F., Pàrdutz, A., Tajti, J., Vécsei, L. and Toldi, J. (2013) Unexpected Effects of Peripherally Administered Kynurenic Acid on Cortical Spreading Depression and Related Blood-Brain Barrier Permeability. Drug Design, Development and Therapy, 16, 981-987
[16]  Curto, M., Lionetto, L., Negro, A., Capi, M., Fazio, F., Giamberardino, M.A., et al. (2015) Altered Kynurenine Pathway Metabolites in Serum of Chronic Migraine Patients. The Journal of Headache and Pain, 17, 47.
https://doi.org/10.1186/s10194-016-0638-5
[17]  Diener, H.C., et al. (2005) Efficacy and Safety of 6.25 mg t.i.d. Feverfew CO2-Extract (MIG-99) in Migraine Prevention—A Randomized, Double-Blind, Multicentre, Placebo-Controlled Study. Cephalalgia, 25, 1031-1041.
https://doi.org/10.1111/j.1468-2982.2005.00950.x
[18]  Tassorelli, C., et al. (2005) Parthenolide Is the Component of Tanacetum Parthenium That Inhibits Nitroglycerin-Induced Fos Activation: Studies in an Animal Model of Migraine. Cephalalgia, 25, 612-621.
https://doi.org/10.1111/j.1468-2982.2005.00915.x
[19]  Materazzi, S., Benemei, S., Fusi, C., et al. (2013) Parthenolide Inhibits Nociception and Neurogenic Vasodilatation in the Trigeminovascular System by Targeting the TRPA1 Channel. Pain, 154, 2750-2758.
https://doi.org/10.1016/j.pain.2013.08.002
[20]  Sun-Edelstein, C. and Mauskop, A. (2009) Role of Magnesium in the Pathogenesis and Treatment of Migraine. Expert Review of Neurotherapeutics, 9, 369-379.
https://doi.org/10.1586/14737175.9.3.369
[21]  Mody, I., Lambert, J.D. and Heinemann, U. (1987) Low Extracellular Magnesium Induces Epileptiform Activity and Spreading Depression in Rat Hippocampal Slices. Journal of Neurophysiology, 57, 869-888.
https://doi.org/10.1152/jn.1987.57.3.869

Full-Text


comments powered by Disqus